
View larger version (46K):
[in a new window]
|
Fig. 6. Ras/Raf-1/MEK1/2 activation. CHO Vß3 cells were treated as described in Fig. 2 and probed for detection of (A) GTP-Ras (diluted 1:800), (B) serine- (diluted 1:500; left panels) and (C) tyrosine- (diluted 1:1000; right panels) phosphorylated Raf-1, co-precipitated PKC (left panels) and c-Src (right panels). An aliquot of cells in standard culture conditions was serum-starved overnight, then treated with 20% FBS for 30 minutes to show the integrity of the Raf-1 pathway (B,C). In A, the GTP analogue, GTP S, and GDP were added in the assay for positive and negative control, respectively. (D) CHO Vß3 and (E) osteoclasts were treated as described above in the presence of the Raf-1 inhibitor 5-iodo-3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2-indolinone (Raf-1 in; 15 µM, 30 minutes) prior to treatment with 20% FBS or plating on LM609-coated wells for 30 minutes. Cells were then processed for SDS-PAGE and western blot for detection of total and phosphorylated Raf-1 and ERK1/2. (F) CHO Vß3 cells and (G) osteoclasts were treated as above but in the absence of the inhibitor, lysed and tested for Raf-1 kinase activity using the Upstate Raf-1 kinase cascade assay kit. (H,I) Lysates from (H) CHO Vß3 cells and (I) osteoclasts were also tested using the MEK1/2 immunoprecipitation kinase assay kit for detection of MEK1/2 kinase activity. Similar results were obtained in three independent experiments. IP, immunoprecipitation; TCL, total cell lysate; WB, western blot analysis; Susp, cells in suspension; LM609, adhesion to LM609 for 30 minutes. For F-I results are the mean ± s.e.m. of three independent experiments, with *P<0.0001.
|